In 17 of 22 (77.3%) patients, CT83 was expressed at either of the two or both of the two non-tumor sites at significantly higher rates than in the remaining GC patients (45.7%, p = 0.0276, Supplementary Table S3). This evidence concerns the gene CT83 and neoplasm.